Earnings ·
Eton reports Q3 revenue of $57.9M and raises full-year guidance to over $175M
ETONEton Pharmaceuticals, Inc.
Eton Pharmaceuticals reported third-quarter 2026 net revenue of $57.9 million, a 158% increase from the prior year period, driven by sales of HEMANGEOL and growth across its rare disease portfolio. The company achieved fully diluted GAAP earnings per share of $1.06 and Adjusted EBITDA of $28.5 million, representing a 49% margin. Management raised full-year 2026 revenue guidance to more than $175 million from over $145 million and increased the Adjusted EBITDA margin outlook to at least 40%, up from 35%. The firm also highlighted pipeline milestones including FDA acceptance of a KHINDIVI label expansion submission and the initiation of an ET-900 study for epileptic spasms. Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.